As we close out the first quarter of 2023, let's take a look at how life sciences executives can conduct better M&A deals despite this unpredictable business environment.
Article |
By Dr. Martin Schilling,Evonik Corporation
The market for biological drugs continues to grow at an impressive pace over the past years. Explore three key trends that will underpin the sustainable growth of biopharma beyond COVID-19.
The need for optimized apheresis collections is a critical first step in the manufacture of many cell therapy products. Highly variable or poor quality starting apheresis collections present a significant engineering and manufacturing development challenge.
Microfluidic mixing is one of the most effective means to formulate lipid nanoparticles (LNPs) for its scalability and reproducibility. Explore LNP formulation, polishing, sterile filtration of mRNA-LNPs, and more.
Based on a panel discussion at the Cell & Gene Meeting on the Mesa in October 2022, gain insight from a panel of experts on the future of advanced therapies.
Read how the incorporation of transfer sets designed to support CGTs will aid in the implementation of controllable, consistent, and safe cGMP amenable manufacturing procedures.
Explore this transfection reagent's benefits and learn why it is often chosen for virus production runs in most adherent and suspension cell culture systems.
Explore the impact of the 4G/5G transition on the life sciences supply chain, how this change can resolve current supply chain issues, and precautions to take when adopting 5G-enabled technologies.
Panelists from Lonza, Takeda, and Vor Biopharma share their insights on how to best introduce disruptive technologies into cell therapy manufacturing processes.
